Algert Global LLC Purchases 205,286 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Algert Global LLC grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 176.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,633 shares of the biopharmaceutical company’s stock after acquiring an additional 205,286 shares during the period. Algert Global LLC owned 0.33% of Ultragenyx Pharmaceutical worth $9,675,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Assetmark Inc. grew its stake in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $55,000. Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,169 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the period. 97.67% of the stock is owned by institutional investors.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 1,632 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $37,209.60. Following the completion of the transaction, the chief accounting officer directly owned 48,670 shares of the company’s stock, valued at $1,109,676. This represents a 3.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 1,635 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $22.40, for a total transaction of $36,624.00. Following the sale, the chief financial officer owned 85,034 shares of the company’s stock, valued at approximately $1,904,761.60. The trade was a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 104,958 shares of company stock valued at $2,394,858 in the last three months. 5.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Guggenheim lowered their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Barclays dropped their price objective on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, November 24th. Jefferies Financial Group cut their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Bank of America lowered their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Finally, Leerink Partners dropped their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.76.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $21.34 on Monday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37. The company has a market capitalization of $2.06 billion, a PE ratio of -3.65 and a beta of 0.16. The business has a fifty day moving average price of $23.01 and a two-hundred day moving average price of $28.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.